Ori Capital is a private equity firm that specializes in growth capital and buyout investments. The firm focuses on partnering with companies in high-growth sectors, providing them with the capital and strategic guidance necessary to scale their operations and achieve their business objectives.

Founded in 2015, ORI Capital is a healthcare venture capital firm that invests in innovative early-stage biotech companies globally. ORI Capital leverages a proprietary quantimental strategy combining AI assisted big data with fundamental research and an experienced team of healthcare specialists to invest in the areas of diagnostics, drug delivery, and therapeutics focused on disease areas with the highest mortality rates including cancer, cardiovascular, and neurodegenerative diseases. ORI Capital’s mission is to be both financially successful for its investors and socially impactful for patients worldwide.

Orchard Therapeutics

Semma Therapeutics

Kymab

ORI Capital

We are thrilled to announce that the FDA has approved Lenmeldy, the only therapy for eligible children with early-onset metachromatic leukodystrophy in the U.S. Read more in our press release: https://bit.ly/4ceTmzr.

We’re honored to be named a #Fierce15 medtech company for 2023 by Fierce Biotech and to have our #enFuse wearable recognized as a technology transforming treatment experiences for patients and providers.
Read our spotlight to learn how we’re bringing forward a more comfortable, convenient, and discreet way to administer medications requiring an injection. https://lnkd.in/eUDaU-Nm

🚀 We're thrilled to announce our second fund is closed at $260M!
🤝 Big thanks to our partners, investors, and team.
🔗 Explore our feature on The Wall Street Journal, https://lnkd.in/gCcugbrX 

#ORICapital #LifeSciences #VentureCapital #Biotech #Innovation #WSJ


COM:ORI-CAPITAL

Ori Capital

Analysis Not Available